NL-OMON52175招募中4 期
Chronotherapy in Inflammatory Arthritis (ChronIA trial): a randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-release - ChronIA trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this study, a subject must meet all
- •of the following criteria:
- •- RA or PsA, according to respectively the ACR/EULAR 2010 criteria for RA and
- •CASPAR criteria
- •- Active disease, respectively defined as a DAS>2.4 or DAPSA>14
- •- Age >=18 years
排除标准
- •- Current or previous treatment of arthritis with tsDMARD(s)
- •- Prednisone (or equivalent) usage at a dose of >7.5mg
- •- Work in shifts
- •- (Relative) contraindications for study medication:
- •a. Evidence of ongoing infectious or malignant process obtained within 3 months
- •prior to screening and evaluated by a qualified health care professional.
- •b. Pregnant or nursing (lactating) women.
- •c. Female participants of child bearing potential and male participants whose
- •partner is of child bearing potential who are not willing to ensure that they
- •or their partner use effective contraception during the trial and for 3 months
- •thereafter as in standard practice.
- •d. History of clinically significant liver disease or liver injury as indicated
- •by abnormal liver function tests (LFT) such as aspartate aminotransferase/serum
- •glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/ serum
- •glutamic pyruvic transaminase (ALT/SGPT), alkaline phosphatase, or serum
- •bilirubin. The Investigator should be guided by the following criteria: Any
- •single parameter may not exceed 2 x upper limit of normal (ULN). A single
- •parameter elevated up to and including 2 x ULN should be re-checked once more
- •as soon as possible, and in all cases, at least prior to
- •enrolment/randomization, to rule out laboratory error.
- •e. History of renal trauma, glomerulonephritis, or subjects with one kidney
- •only, or a glomerular filtration rate (GFR) <30 ml/min.
- •f. Other underlying metabolic, hematologic, renal, hepatic, pulmonary,
- •neurologic, endocrine, cardiac, infectious or gastrointestinal conditions which
- •in the opinion of the Investigator immunocompromises the patient and/or places
- •the patient at unacceptable risk for participation in an immunomodulatory
- •g. Use of powerful CYP3A4 inhibitors (e.g. ketoconazole, fluconazole,
- •tacrolimus and ciclosporin)
- •- Unable to understand, speak and write in Dutch.
研究者
相似试验
进行中（未招募）
1 期
Comparing the effectiveness of tofacitinib extended release (XR) chronotherapy, morning versus evening dosing, in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients from a patient’s, clinical as well as a translational point of view.Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteriaMedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-004131-84-NLErasmus Medical Center84
进行中（未招募）
4 期
Comparing the effectiveness of morning and evening dosing of tofacitinib in inflammatory arthritisInflammatory arthritis (rheumatoid arthritis and psoriatic arthritis)Musculoskeletal DiseasesRheumatoid arthritis, unspecified, Other psoriatic arthropathiesISRCTN68663074Erasmus MC84
已完成
不适用
Development of chronotherapeutics in rheumatoid arthritisrheumatoid arthritisJPRN-UMIN000040094Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University120
尚未招募
4 期
Innovative Approaches to Inflammatory Arthritis: Efficacy and Safety of non-invasive transcutaneous auricular vagus nerve stimulation (IA-taVNS)Rheumatoid arthritis, SpondyloarthritisJPRN-UMIN000053649Hokkaido University20
已完成
1 期
RA morning stiffness studyRheumatoid arthritis, morning stiffnessD001172Rheumatoid ArthritisJPRN-jRCTs052210155Shima Yoshihito20